Cavidi raises over $1 million
Cavidi AB has signed an agreement with a consortium of American and Swedish investors, raising over $1.0 million to drive forward Cavidi's newly adopted three-year business plan.
Cavidi AB
(Sweden) has signed an agreement with a consortium of American and Swedish investors. The consortium has provided over $1.0 million of operational funding, and has committed to raising additional funding as necessary. The capital will be used to drive forward Cavidi's newly adopted three-year business plan. Cavidi produces ExaVir Load, an HIV viral load assay suited for resource-limited settings.
The key members of the investment consortium include several American investors experienced in venture capital markets as well as senior Cavidi management. The three-year plan they are funding seeks to generate more than a five-fold growth in revenue. It will capitalize on the recent release of Cavidi's ExaVir Load Version 3 - a new and improved version of their HIV viral load assay. It is also part of the plan to appoint additional distributors in Asia. Further investment will be required in both working capital and equipment in order to undertake a major expansion in production capacity.
The consortium will appoint a new member to Cavidi's board of directors. They have also committed to raising additional capital over the life of the three-year plan as needed.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
